PRGN-3006

· Precigen, Inc

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PRGN-3006, covering 2024-11-08 to 2024-11-08. Get the full timeline:

Most recent: Clinical Trial Update: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS [Phase 1]

See pricing